Tag: biomedical
-
Antibodies to Treat Cancer Complication Licensed to Pharma
17 August 2015. Aveo Oncology, a developer of biopharmaceuticals for cancer and related diseases, is licensing its engineered antibody designed to treat cachexia, a complication of cancer and other disorders, to the pharmaceutical company Novartis. The agreement could bring Aveo as much as $326 million over the course of the collaboration. Cachexia is a metabolic…
-
Challenge Seeks Interventions for Epilepsy
14 August 2015. In a new challenge on InnoCentive, the Epilepsy Foundation is seeking methods and interventions to reduce sudden unexpected death in epilepsy, or SUDEP. The competition has a purse of $30,000 and deadline for submissions of 13 October 2015. InnoCentive in Waltham, Massachusetts conducts open-innovation, crowdsourcing competitions for corporate and organization sponsors. Free…
-
Inside Air Monitor Devised as Smartphone Add-On
13 August 2015. Engineers in Finland designed a miniaturized system for measuring levels of carbon dioxide and other gases with smartphones to monitor interior air quality for health care needs. The team at VTT Technical Research Centre, an applied research institute in Finland, developed the monitor as an add-on to mobile devices, with a spin-off…
-
Genetic Test Found to Save Drug Expense, Boost Adherence
13 August 2015. A genetic test to guide the choice of drugs prescribed to patients with psychiatric disorders was found to reduce the cost of medications to those patients and improve adherence to the drugs prescribed, compared to patients who were not given the test. Results of the study evaluating the GeneSight test, made by…
-
Blood Disease Biotech Gains $120 Million in IPO
12 August 2015. Global Blood Therapeutics, a biotechnology company developing treatments for blood-related disorders, is raising $120 million in its initial public stock offering. The company, in South San Francisco, California and trading on the Nasdaq exchange under the symbol GBT, issued 6 million shares priced at $20.00. Shares closed today trading at $43.50, more…
-
Protein Gels Being Devised to Simulate Human Functions
12 August 2015. New York University’s engineering school is developing a new type of protein-based gel materials that respond to and replicate natural biochemical processes. The three-year project, led by chemical and biomolecular engineering professor Jin Kim Montclare, is funded by a $368,000 grant from the U.S. Army Research Laboratory. Montclare and colleagues, at NYU’s…
-
Trial Shows Fertility Treatment Boosts IVF Pregnancy Rate
11 August 2015. A clinical study of cellular treatments for women using in-vitro fertilization shows the treatments increased pregnancy rates compared to women receiving standard IVF alone. Findings from the study that tested treatments developed by IVF technology company OvaScience Inc. in Cambridge, Massachusetts are scheduled to be published on 25 August in the Journal…
-
Intrexon Acquires Oxitec, Partners on Genetic Disorder
10 August 2015. Intrexon Corp., a biotechnology company specializing in synthetic biology, is acquiring Oxitec Ltd., a designer of genetically modified insects to control the spread of disease-bearing and agricultural pests for $160 million. Intrexon is also partnering with Synthetic Biologics Inc. to develop therapies for phenylketonuria, a genetic metabolic disorder. Intrexon, in Gaithersburg, Maryland…
-
Nicotine Destroying Drug Candidate Discovered
7 August 2015. Biochemists at Scripps Research Institute reported on an enzyme derived from naturally-occurring bacteria that shows in lab tests can remove nicotine in the blood, with potential as a drug to help smokers quit. The team from the lab of chemistry professor Kim Janda at Scripps’s La Jolla, California campus described their findings…
-
Peanut Allergy Therapy Company Raises $160 Million in IPO
6 August 2015. Aimmune Therapeutics Inc., a developer of treatments for peanut and other food allergies, raised $160 million from its initial public stock offering, pricing its 10 million shares at $16.00. Shares in the Brisbane, California company trade on the Nasdaq exchange under the symbol AIMT. Shares closed today (6 August), priced at $24.10…